These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12678861)

  • 21. Monoclonal antibodies as anti-infective products: a promising future?
    Pelfrene E; Mura M; Cavaleiro Sanches A; Cavaleri M
    Clin Microbiol Infect; 2019 Jan; 25(1):60-64. PubMed ID: 29715552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody based target tailored antimicrobial chemotherapy - a new approach.
    Singla M
    Med Hypotheses; 2007; 68(5):957-9. PubMed ID: 17141970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications.
    McKinnon JE; Maksimowicz-McKinnon K
    Transl Res; 2016 Jan; 167(1):46-60. PubMed ID: 26408802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of pattern-recognizing receptors in anti-infectious immunity].
    Tukhvatulin AI; Shcherbinin DN; Logunov DIu; Shmarov MM; Naroditskiĭ BS
    Vestn Ross Akad Med Nauk; 2011; (10):47-54. PubMed ID: 22168039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Complement in Antibody Therapy for Infectious Diseases.
    Wibroe PP; Helvig SY; Moein Moghimi S
    Microbiol Spectr; 2014 Apr; 2(2):. PubMed ID: 26105816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Human Antibody Libraries for Infectious Diseases.
    Chan SK; Lim TS
    Adv Exp Med Biol; 2017; 1053():61-78. PubMed ID: 29549635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity.
    Lavelle EC; McLachlan JB
    Curr Opin Pharmacol; 2018 Aug; 41():vii-ix. PubMed ID: 30139514
    [No Abstract]   [Full Text] [Related]  

  • 28. A tug-of-war between the host and the pathogen generates strategic hotspots for the development of novel therapeutic interventions against infectious diseases.
    Rana A; Ahmed M; Rub A; Akhter Y
    Virulence; 2015; 6(6):566-80. PubMed ID: 26107578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.
    Dixit R; Herz J; Dalton R; Booy R
    Vaccine; 2016 Feb; 34(9):1152-61. PubMed ID: 26802604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging paradigms in anti-infective drug design.
    Barrett MP; Croft SL
    Parasitology; 2014 Jan; 141(1):1-7. PubMed ID: 24401336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of nanotechnologies for improved immune response against infectious diseases in the developing world.
    Look M; Bandyopadhyay A; Blum JS; Fahmy TM
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):378-93. PubMed ID: 19922750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Technological Evolution in the Development of Therapeutic Antibodies.
    Fajardo-Ramírez ÓR; Ascacio-Martínez JA; Licea-Navarro AF; Villela-Martínez LM; Barrera-Saldaña HA
    Rev Invest Clin; 2015; 67(3):158-69. PubMed ID: 26202739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naïve Human Antibody Libraries for Infectious Diseases.
    Chan SK; Rahumatullah A; Lai JY; Lim TS
    Adv Exp Med Biol; 2017; 1053():35-59. PubMed ID: 29549634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-based therapies for emerging infectious diseases.
    Casadevall A
    Emerg Infect Dis; 1996; 2(3):200-8. PubMed ID: 8903230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive antibody therapy for infectious diseases.
    Casadevall A; Dadachova E; Pirofski LA
    Nat Rev Microbiol; 2004 Sep; 2(9):695-703. PubMed ID: 15372080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory roles of B cells in infectious diseases.
    Fillatreau S
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):1-5. PubMed ID: 27586794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance.
    Cassell GH; Mekalanos J
    JAMA; 2001 Feb; 285(5):601-5. PubMed ID: 11176866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer immunotherapy: accomplishments to date and future promise.
    Helmy KY; Patel SA; Nahas GR; Rameshwar P
    Ther Deliv; 2013 Oct; 4(10):1307-20. PubMed ID: 24116914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cells that mediate innate immune memory and their functional significance in inflammatory and infectious diseases.
    Gardiner CM; Mills KH
    Semin Immunol; 2016 Aug; 28(4):343-50. PubMed ID: 26979658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.